In 2024, Square Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).
However, Square Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
| Metric (tCO2e) | 2024 |
|---|---|
Total Scope 1 | 59,705a |
Total Scope 2 | |
Unspecified Calculation Method | 4,387a |
Total Scope 3 | N/A |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 104.0711a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2024, the total operational greenhouse gas (GHG) emissions of Square Pharmaceuticals amounted to 64,092 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
In 2024, the total Scope 1 emissions of Square Pharmaceuticals were 59,705 metric tons of CO₂ equivalent (tCO₂e).a
In 2024, Square Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 4,387 tCO₂e without specifying the calculation method.a
In 2024, Square Pharmaceuticals reported its Scope 2 emissions using an unspecified methodology.a
In 2024, Square Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 59,705 tCO₂e and total revenues of USD 574 millions. This translates into an emissions intensity of 104.07 tCO₂e per millions USD.a
In 2024, Square Pharmaceuticals reported a Scope 1 emissions intensity of 104.07 tCO₂e per millions USD. Compared to the peer group median of 10.33, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Square Pharmaceuticals ranked 21 out of 22 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Square Pharmaceuticals among the least efficient performers, with one of the highest emissions intensities in its sector.a